Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20060011914external-prioritypatent/EP1733931B1/en
Application filed by Sanol Arznei Schwarz GmbhfiledCriticalSanol Arznei Schwarz Gmbh
Publication of CR20140109SpublicationCriticalpatent/CR20140109S/en
Una composición farmacéutica que comprende un solvato farmacéuticamente aceptable de fesoterodina o de una sal farmacéuticamente aceptable de la misma, y un estabilizador farmacéuticamente aceptable.A pharmaceutical composition comprising a pharmaceutically acceptable solvate of fesoterodine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable stabilizer.
CR20140109F2006-06-092014-03-03
STABILIZING PHARMACEUTICAL COMPOSITIONS THAT INCLUDE FESOTERODINE
CR20140109S
(en)
COMPOUNDS DERIVED FROM FTALAZINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT VASCULAR DISEASES, SEPTIC SHOCK, ISCHEMICAL INJURIES, NEUROTOXICITY, HEMORRAGICAL SHOCK, VIRAL INFECTIONS, AMONG OTHERS.
Compound 4- [5 (2-amino-ethanesulfonyl) -isoquinolin-7-yl] -phenolo a pharmaceutically acceptable salt or a hydrate or salt thereof; pharmaceutical composition comprising said compound, lyophilized pharmaceutical composition; and use of the compound as antineiplasic and / or antiviral.